Pfizer/Corvas agreement focuses on NIF for stroke; Pfizer extends Neurogen agreement.
Executive Summary
PFIZER/CORVAS AGREEMENT FOCUSES ON NIF FOR STROKE, the companies announced Oct. 16. Pfizer has licensed rights to Corvas' neutrophil inhibitory factor, which is in preclinical studies for prevention of brain tissue damage after a stroke. Corvas believes that NIF may limit the damage caused by the inflammatory response triggered by an ischemic event. NIF blocks the activation of neutrophils, their adhesion to blood vessel walls and their subsequent migration into tissue, according to Corvas.